Long-term comparison of apical versus asymmetric hypertrophic cardiomyopathy

Sung-Hwan Kim1, Seon-Ok Kim, Seungbong Han

  • 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea.

Insights

Apical hypertrophic cardiomyopathy (HCM) has similar survival to asymmetric HCM, but asymmetric HCM carries a higher risk of cardiac death. Beta-blocker use improved long-term outcomes for both hypertrophic cardiomyopathy types.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Apical hypertrophic cardiomyopathy (HCM) is often considered less severe than asymmetric HCM.
  • Direct comparisons of clinical features and long-term outcomes between apical and asymmetric HCM are limited.

Purpose of the Study:

  • To compare electrocardiographic findings and long-term mortality between patients with apical HCM and asymmetric HCM.
  • To identify predictors of long-term outcomes in HCM patients.

Main Methods:

  • Retrospective study of 796 patients (243 apical HCM, 553 asymmetric HCM).
  • Long-term all-cause and cardiac mortality assessed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM).

Main Results:

  • Asymmetric HCM showed significantly more QT prolongation, QRS widening, PR prolongation, and pathologic Q waves.
  • Overall survival rates were similar (borderline significant difference: IPTW/PSM P=0.05).
  • Asymmetric HCM was associated with significantly higher cardiac mortality (IPTW/PSM P=0.03). Beta-blocker use correlated with lower overall death.

Conclusions:

  • While overall survival is comparable, asymmetric HCM presents a higher risk for cardiac death than apical HCM.
  • No specific electrocardiographic predictor for long-term outcomes was identified.
  • Beta-blocker therapy is associated with improved long-term survival in HCM patients.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...